FDA concerned Cardinal Health failed to mitigate risk of non-syringes with patient-controlled pain management. CEO Deborah Weitzman sold 6,712 shares in a transaction on Monday, August 28th. CEO Weitzmann sold 6.

Cardinal Health Inc. stock rises monday, outperforms market - marketwatch.com. FDA warns against using Cardinals syringes. FDA concerned Cardinal Health failed to mitigate risk of non-syringes with patient-controlled pain management. StockNews.com assumed coverage on shares of Cardinal Health in a research report on Thursday, October 5th. CEO Deborah Weitzman sold 6,712 shares in a transaction on Monday, August 28th. TheStreet upgraded shares of Card Health from a “c” rating to a ‘b-’ rating. Cardinal Health stock has gained 108% since 2019 primarily due to favorable change in revenues. CAH Stock has gained more than 100% since the start of the year. Cardinal Health Board of Directors approves quarterly dividend of $0.5006 per share. Cardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products. Cardinal Health, Inc. – Consensus ‘hold rating and 4.8% upside potential. Cardinal Health has less short interest than most of its peers. FDA warns against using Cardinals syringes November 20, 2023 at 12:48 PM (Reuters) FDA warns not to use Cardinal Healths Monoject syringles with patient-controlled pain management pumps and syringe pumps. FDA believes using these products “may cause serious injuries or death”